

Special Issue

EPH and Ephrins in Pathogenesis and as Drug Target

Message from the Guest Editors

Thirty-five years later the discovery of the first EPH gene by Takaku's group, Eph receptors and the ephrin ligands constitute a complex and redundant cellular communication network. Nowadays a wide plethora of biological techniques and pharmacological tools are available to investigate the roles and the potential benefits of Eph/ephrin targeting in several diseases. Unfortunately, despite the research efforts, drugs targeting this system have not reached the market yet, and the gap between the bench and the bed still exists. The present Special Issue of *Pharmaceuticals* aims to be not only a synthesis of the meeting Eph/ephrin system (www.ephrins.org) we recently organized, but also an opportunity for all the scientists in this field. This special issue purposes to collect the most updated works and to be a valid source of inspiration for future research in the field of Eph/ephrin targeting. We sincerely hope that you will be able to submit your original contributions in this Special Issue, that want to be a valuable piece of the state of the art on Eph/ephrin targeting puzzle.

Guest Editors

Dr. Massimiliano Tognolini

Prof. Dr. Jiangping Wu

Dr. Carmine Giorgio

Deadline for manuscript submissions

closed (23 December 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/126330

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)